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Abstract
Background: Pain is highly prevalent in Parkinson’s disease (PD), impacting patients’ ability, 
mood, and quality of life. Detecting the presence of pain in its multiple modalities is necessary 
for adequate personalized management of PD. A 14-item, PD-specific, patient-based
questionnaire (the King’s Parkinson’s disease Pain Questionnaire, KPPQ) was designed 
corresponding to the rater-based KPP Scale (KPPS). The present multi-center study was aimed 
at testing the validity of this screening tool. Methods: First, a comparison between the KPPQ 
scores of patients and matched controls was performed. Next, convergent validity,
reproducibility (test-retest), and diagnostic performance of the questionnaire were analyzed.     
Results: We report data from 300 patients and 150 controls. PD patients declared significantly 
more pain symptoms than controls (3.96±2.56 vs. 2.17 1.39; p<0.0001). KPPQ convergent 
validity with KPPS total score was high (rS = 0.80), but weak or moderate with other pain 
assessments. Test- ,
Dyskinetic pains (kappa=0.44) and ICC for the KPPQ total score 0.98.  
present), a high agreement was found between the KPPQ and the KPPS (ICC =0.88). A strong 
correlation (rS = 0.80) between both instruments was found. The diagnostic parameters of the 
KPPQ were very satisfactory as a whole, with a global accuracy of 78.3%-98.3%.
Conclusions: These results suggest that the KPPQ is a useful, reliable, and valid screening 
instrument of pain in PD to advance patient-related outcomes.
Key words:  Parkinson’s disease; Pain; Assessment; Screening; King’s Parkinson’s disease 
Pain Questionnaire; KPPQ; Validation
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Introduction
The prevalence of pain in PD has been estimated to be around 68% (range: 40%-85%) 
[1]. However, pain in PD is still underdiagnosed and often undeclared [2], and only about half 
(52.4%) of PD patients with pain use analgesics [1].
Furthermore, PD patients with pain are more likely to suffer from anxiety, depression, 
and worsened sleep quality [3]. Pain has also been shown to interfere with work and other 
activities of daily living to some extent in these PD patients [4,5]. Because of the multi-
dimensional effect of pain in PD, it is one of the most relevant determinant factors of health-
related quality of life in general [6] and in PD [7,8].
Several types of pain may be present in PD (e.g. dystonic, musculoskeletal, central, and
radicular) [9] and accumulate in a single patient, complicating the management of this non-
motor symptom [10]. Moreover, the pathophysiology of pain in PD is complex, with peripheral-
(rigidity, dystonia), spinal cord- (intermediolateral cell column), and brain-related (deficiency of 
monoamines in the brain stem) origins [11,12].
Due to their inherent difficulty for assessment, the rater-based King’s Parkinson’s 
disease Pain Scale (KPPS) was developed to evaluate the multiple pain modalities present in 
PD patients [13]. However, the KPPS is administered by healthcare professionals; therefore, a
need for a valid patient-completed questionnaire exists. For this reason, the King’s College 
Parkinson’s Disease Pain Questionnaire (KPPQ) was created with the support of CRISP 
(Community for Involvement and Support for people with Parkinson’s), an expert patient group 
based at King’s College Hospital, to ensure comprehensibility for laypersons by using 
appropriate wording and logically ordering the questions.
The KPPQ (Appendix 1), a time-efficient and easy-to-understand 14-item screening 
questionnaire is composed solely of “Yes” or “No” questions that assess whether or not a 
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specific type of pain is present, similarly to the widely-used Non-Motor Symptoms Questionnaire
[14]. Since the patient-completed KPPQ is a derivative of the rater-completed KPPS, each 
question of the KPPQ corresponds to one of the items of the KPPS. Even though the KPPQ 
does not use domains to group these 14 items, both the KPPS and the KPPQ address the same 
specific types of pain. 
The objective of this multicenter study is to determine the validity and reliability of the 
KPPQ using a sample of PD patients and healthy controls.  
Methods
Design
International, multi-center, observational, cross-sectional study.
Patients
Consecutive PD patients with a diagnosis of PD (according to the UK PD Brain Bank criteria)
[15] who answered “Yes” to question 10 of the Non-Motor Symptoms Questionnaire,
“Unexplained pains (not due to known conditions),” [14] were included in this study. Exclusion 
criteria were: (1) Patients with alternative or uncertain diagnosis of Parkinson’s and drug-
induced Parkinson’s; (2) inability to give consent; (3) presence of dementia formally diagnosed 
following internationally-accepted criteria; and (4) diagnosis of identifiable conditions causing 
pain unrelated to PD (e.g. severe osteoarthritis, known malignancy, rheumatoid arthritis, 
polymyalgia rheumatica, fibromyalgia, etc.).
For this study, a sample size of 300 patients was proposed considering both the potential 
variability and confounding effect of a patient-completed assessment and the number of 
participating sites.
Patients were recruited from August 2013 to February 2016 from movement disorder units of 
nine different centers across the UK as well as Romania. In the UK, the study was adopted to 
the National Institute of Health Research portfolio of studies (UKCRN No. 13344).
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Controls
A sample of 150 controls (ratio of patients:controls = 2:1) matched by age and sex was 
assessed by means of the KPPQ. Exclusion criteria overlapped exclusion criteria 2 through 4 for 
patients.
Assessments
For both patients and controls, information regarding socio-demographic and PD historical data 
were recorded.
In addition to the KPPQ, the following instruments for PD were applied (see Supplementary 
material for details): KPPS [13], Hoehn and Yahr classification (HY) [16], Scales for Outcomes 
in Parkinson’s Disease-Motor (SCOPA-Motor) [17], Non-Motor Symptoms Scale (NMSS) [18],
Clinical Impression of Severity Index for PD (CISI-PD) [19], Visual Analog Scales (VAS) for pain 
severity and frequency [20], Hospital Anxiety and Depression Scale (HADS) [21], EQ-5D [22],
PD Quality of Life Questionnaire (PDQ-8) [23], and Parkinson’s Disease Sleep Scale-Version 2 
(PDSS-2) [24].
Levodopa Equivalent Dose (LEDD) was calculated according to Tomlinson et al. 2010 [25].
In the control group, the following assessments were collected: KPPQ, HADS, and EQ-5D.
Procedures
Patients were assessed in the optimally “on” state. Test-retest reliability of the KPPQ was 
evaluated by means of a second application of the questionnaire in patients who remained 
stable with respect to pain as per the pain VAS.
Ethical Issues
This study was approved by the hospital ethical committees/institutional review boards of the 
participant centers. All participants provided informed consent prior to joining the study.
Data Analysis
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For each participant, a KPPQ “total score” (KPPQ-TS) was calculated by summing the number 
of “Yes” responses. Also, to compare the performance of the KPPQ with the KPPS that was 
taken as “gold standard,” the KPPQ items were grouped in domains according to those of the 
scale. For both the NMSQ and NMSS, the prevalence of the diverse types of pain was 
determined by the proportion of individuals responding positively each item ( ), 
considering a score of 0 as the absence of the symptom.
Distribution of data was not normal (Shapiro-Francia test); therefore, non-parametric statistics 
were used. The differences between patients and controls were analyzed using the chi-square,
Mann-Whitney U, and McNemar chi-square tests. Association between measures was 
determined by the Spearman rank correlation coefficient. A high correlation (rS >0.70) of the 
KPPQ-TS with KPPS total score was hypothesized, whereas moderate or weak correlations (rS=
0.70) [26] were expected with other variables.
For concordance between the prevalence detected by corresponding items of KPPQ and KPPS,
and for test-retest reliability, Cohen’s kappa index for items, and ICC for total scores were 
determined.
Finally, sensitivity, specificity, positive and negative predictive values, and accuracy of the 
KPPQ were calculated against the corresponding components of the KPPS. 
For more detail, see the Supplementary material.
Results
We report data from 300 patients and 150 controls matched by age and gender. There were no 
significant differences between patients and controls in reference to age (mean SD: 
64.86 10.54 vs. 64.86 10.23; p=0.90), sex (males, 59.7% vs. 60%; p=0.95), ethnics (p=0.63),
and education years (14.11 3.99 vs. 14.39 3.93; p=0.33). Median (and interquartile range) HY 
of patients was 2 (2 – 3; limits: 1–5).
HADS and EQ-5D assessments showed significantly higher levels of depression (6.62 4.39), 
anxiety (5.45 3.82), and worse quality of life (0.57 0.27) in PD patients when compared to the 
levels of depression (5.09 3.57), anxiety (3.90 3.01), and overall quality of life (0.78 0.22) in
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controls (p<0.0001 to p=0.0006). Significant differences were also found in the proportion of 
subjects with positive responses on the KPPQ for 50% of the items and three out of the seven 
domains after Bonferroni correction (Table 1). When comparing KPPQ-TS, patients declared
more pain symptoms than controls (3.96±2.56 vs. 2.17 1.39; p<0.0001).
In patients, the proportion of positive responses to the KPPQ was compared with those of the 
KPPS, and a significant difference was found in only one item (6. Painful cramps during off 
periods) of the KPPQ and one domain (3. Fluctuation-related pain) (Table 1).
The agreement between KPPQ and KPPS prevalence showed kappa values from 0.56 (KPPQ 
items 6 and 7) to 0.86 (item 14), with 11 items (78.6%) reaching kappa values greater than 0.60 
(substantial agreement). Overall, the KPPQ-TS and KPPS “total score of prevalence” displayed 
a high level of concordance (ICC =0.88).
Table 2 shows the correlations of the KPPQ-TS with other pain measures. While a tight 
correlation with the KPPS total score (rS=0.80) was found, coefficients were weak/moderate with 
the other pain measures (rS=0.31-0.46). The KPPS total score, however, showed mildly higher 
correlation coefficient values with these pain assessments (rS=0.47-0.50).
To test the reproducibility of the KPPQ, a second application was carried out in 52 patients at a 
mean interval of 11.8 4.4 days (range: 7-28). No significant differences between applications 
were found for the VAS-TS (Wilcoxon signed-rank test; p=0.52) and the KPPQ-TS (p=0.76). 
Kappa values were KPPQ items, with exception of one item (5. Dyskinetic pains;
kappa=0.44) (Table 3). ICC for the KPPQ-TS was 0.98.
The results of KPPQ diagnostic parameters were satisfactory, with values running from 61.4%
to 99.3% (Table 4). The global accuracy of the KPPQ components ranged from 78.3% to 98.3% 
Discussion
This is the first report of a validation of a patient-completed pain questionnaire specifically 
developed for PD. This patient-completed screening tool was derived from the KPPS and allows 
for the direct declaration of the pain each patient experiences.
Prevalent in the prodromal, early, advanced, and palliative stages of PD, pain is one of its most 
important non-motor symptoms [27-29] and was described by James Parkinson himself in his 
case number 4 [30,31]. Neuropathological correlates of pain in early and untreated PD have
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been described, [32] and pain is also featured as one of the most prevalent and troublesome 
symptoms in the late palliative stage of PD [28,33].
Despite the importance and high frequency of pain in PD [34], studies suggest that pain is 
under-reported and often not considered in clinical consultations [2]. In part, this is related to the 
lack of a validated self-declared tool specifically developed considering the diversity of pain in 
PD. KPPQ was developed considering this conceptual framework and to empower patients to 
declare pain.
Our analysis showed that, when the KPPQ was applied in patients and matched controls, the 
prevalence of the different varieties of pain was significantly greater in PD patients in half of the 
pain modalities and in three out of the seven domains. These results are expected because pain 
is experienced by both the elderly and PD patients. However, when considering the differences 
between KPPQ-TS, patients declared significantly more symptoms than controls.
Consistent with previous findings, patients with pain displayed higher rates of depression and 
anxiety [3]. Some estimates show that chronic pain can increase the risk for depression, yet a 
link in the opposite direction is unclear [35,36,37]. It is hypothesized that the link between pain 
and depression could be due to neuroinflammation [36]. In PD, pain-related disability also 
correlates with depression and anxiety [38].
Prior research has shown that pain is a determinant of quality of life in all populations [39] and 
that PD considerably deteriorates patients’ HRQoL [40,41]. The non-motor symptom burden of 
PD, which includes pain, can affect HRQoL with a greater impact than the motor symptoms [42-
45].
The convergent validity of the KPPQ was assessed using other pain measures. While weak and 
moderate correlations were found between these measures and the KPPQ, the KPPS showed 
higher levels of correlations with these scales. However, it is important to note that the KPPQ is 
only a screening tool, whereas the KPPS is a quantitative measure of pain severity and 
frequency in PD and is more closely related to the scales with which both were compared.
Nevertheless, the KPPQ showed moderate correlations with PD-related variables (i.e. SCOPA –
Motor, NMSS, CISI-PD, PDSS-2, and PDQ-8) as well as other measures (i.e. HADS – Anxiety, 
HADS – Depression, and EQ-5D). The weak correlation between the KPPQ and LEDD and 
between the KPPQ and HY staging suggest that there is no relation between PD progression 
and the number of pain symptoms experienced by the patient despite previous findings 
suggesting a relationship between pain and motor impairment severity [4].
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Concerning the reproducibility of the KPPQ, there was significant agreement in each 
item between both applications of the KPPQ, except for one (5. Dyskinetic pains), and for the 
KPPQ-TS. These findings lead to the conclusion that the KPPQ is an instrument with 
satisfactory reproducibility.
When comparing the KPPQ to the KPPS, there were significant differences in the 
proportion of positive responses for only one item and one domain. This can be explained by 
the differences in the wording of the corresponding item in the KPPQ (6. Painful cramps in a 
region during “off” periods) and in the KPPS (5. Pain in a region during “Off” dystonia). 
Otherwise, there was significant agreement between KPPQ and KPPS prevalence for each 
item, suggesting that they are equivalent when the KPPS is used as a screening tool. There 
were also a high level of concordance and a strong correlation between the total scores for both 
instruments.
Finally, the satisfactory capabilities of the KPPQ for screening are clear based on its 
high sensitivity, specificity, and predictive values. Overall, the KPPQ was shown to detect with a 
high accuracy the presence of the diverse pain modalities in PD. Yet, a limitation of our study is 
the assumption that a variety of comorbidities may not cause significantly increased pain and 
may be evenly-distributed among patients and controls. Therefore, we did not control for 
comorbidities that may not necessarily cause pain, such as diabetes.
However, from these results, it is inferred that the KPPQ is a useful, valid, and reliable,
patient-completed instrument to assess pain in PD. We propose that KPPQ be provided to
every patient who answers “yes” to the relevant pain related question in the Non-Motor 
Symptoms Questionnaire, which is now globally applied and regarded as a quality standard for 
the clinical assessment of PD. As both are patient-completed tools, they can be completed while 
waiting to be seen, optimizing consultation time. Utilization of this strategy in clinics would 
ensure that pain is not under-reported or under-recognized in clinical practice.
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Table 1 – Prevalence† of pain modalitites according to the King’s Parkinson’s Disease 
Pain Questionnaire 
Items
KPP Questionnaire KPP Scale
Controls Patients p* Patients p**
1. Pain around joints 77.33 78.67 0.75 81.33 0.046
2. Pain related to internal organ 13.33 19.67 0.096 21.00 0.41
3. Generalised non-specific pain in your 
stomach area
11.33 19.00 0.039 17.67 0.43
4. Pain deep within the body 19.33 32.33 0.0004 31.67 0.77
5. Dyskinetic pain 0 16.67 <0.0001 17.00 0.86
6. Painful cramps in a region during “off” 
periods
11.33 48.33 <0.0001 32.67 <0.0001
7. Generalized “off” period pain 0.67 24.67 <0.0001 22.33 0.31
8. PLM or RLS-associated pain 14.67 32.67 <0.0001 28.00 0.023
9. Pain while turning in bed 18.67 48.33 <0.0001 47.67 0.69
10. Pain when chewing 4.67 6.67 0.40 6.67 1.0
11. Pain due to grinding teeth 6.00 6.00 1.00 5.67 0.74
12. Burning sensation in the mouth 5.33 3.00 0.22 2.67 0.65
13. Burning pain in the limbs 12.00 18.00 0.10 18.33 0.87
14. Shooting pain/pins & needles 22.00 42.33 <0.0001 41.67 0.65
Domains Controls Patients p* Patients p**
1. Musculoskeletal pain 77.33 78.67 0.75 81.33 0.05
2. Chronic pain 30.00 40.00 0.003 40.00 1.0
3. Fluctuation-related pain 12.00 56.33 <0.0001 44.00 <0.0001
4. Nocturnal pain 28.67 57.33 <0.0001 66.00 0.41
5. Oro-facial pain 14.00 13.00 0.71 13.33 0.76
6. Discoloration, oedema/swelling 23.33 31.67 0.009 30.33 0.54
7. Shooting pain/pins & needles 22.00 42.33 <0.0001 41.67 0.65
† Proportion of subjects with positive response.
KPP Questionnaire/Scale: King’s Parkinson’s Disease Pain Questionnaire/Scale.
* Chi-square for prevalence, patients vs. controls.
** McNemar test for prevalence with KPPQ vs. KPPS in patients.
Bonferroni correction: p=0.0024.
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Table 2 – Correlations of the the King’s Parkinson’s Disease Pain Questionnaire 
     total score
Measure Spearman r
With other pain measures KPPS total score
VAS Pain (frequency * severity)
PDQ-8 Item 8
EQ-5D Item Pain/Discomfort
0.80
0.31
0.46
0.32
With PD-related variables SCOPA - Motor 
Non-Motor Symptoms Scale
Clinical Impression of Severity Index-PD 
Parkinson’s Disease Sleep Scale
Parkinson’s Disease Questionnaire-8 items
Hoehn and Yahr staging
Levodopa-equivalent daily dose
0.42
0.47
0.37
0.57
0.56
0.15*
0.24
With other measures HADS – Anxiety
HADS – Depression
EQ-5D 
0.45
0.43
      -0.45
All , except *, p=0.008.
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Table 3 – Test-retest reliability of the King’s Parkinson’s Disease Pain Questionnaire
Items
Agreement
(%)
Kappa
kappa CI 95%
1. Pain around joints 96.2 0.85 0.65 – 1.00
2. Pain related to internal organ 92.3 0.73 0.49 – 0.98
3. Generalised non-specific pain in your stomach area 96.2 0.85 0.65 – 1.00
4. Pain deep within the body 88.5 0.68 0.44 – 0.91
5. Dyskinetic pain 82.7 0.44 0.15 – 0.73
6. Painful cramps in a region during “off” periods 84.6 0.69 0.49 – 0.89
7. Generalized “off” period pain 92.3 0.82 0.65 – 0.99
8. PLM or RLS-associated pain 96.2 0.91 0.78 – 1.00
9. Pain while turning in bed 94.2 0.88 0.75 – 1.00
10. Pain when chewing 96.2 0.65 0.20 – 1.00
11. Pain due to grinding teeth 100 1.00 1.00 – 1.00
12. Burning sensation in the mouth 100 1.00 1.00 – 1.00
13. Burning pain in the limbs 94.2 0.82 0.63 – 1.00
14. Shooting pain/pins & needles 92.3 0.84 0.69 – 0.99
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Table 4 – Screening potential of pain modalities using the King’s Parkinson’s Disease 
Pain Questionnaire when considering the King’s Parkinson’s Disease Pain Scale as the 
gold standard
Items Sensitivity Specificity
Positive 
Predictive Value
Negative 
Predictive Value
Accuracy
1. Pain around joints 95.1% 92.9% 98.3% 81.3% 94.7%
2. Pain related to internal organ 77.8% 95.8% 83.1% 94.2% 92.0%
3. Generalised non-specific pain 
in your stomach area
79.2% 93.9% 73.7% 95.5% 91.3%
4. Pain deep within the body 75.8% 87.8% 74.2% 88.7% 84.0%
5. Dyskinetic pain 66.7% 93.6% 68.0% 93.2% 89.0%
6. Painful cramps in a region 
during “off” periods
90.8% 72.3% 61.4% 94.2% 78.3%
7. Generalized “off” period pain 70.1% 88.4% 63.5% 91.2% 84.3%
8. PLM or RLS-associated pain 85.7% 88.0% 73.5% 94.1% 87.3%
9. Pain while turning in bed 91.6% 91.1% 90.3% 92.3% 91.3%
10. Pain when chewing 80.0% 98.6% 80.0% 98.6% 97.3%
11. Pain due to grinding teeth 76.5% 98.2% 72.2% 98.6% 97.0%
12. Burning sensation in the 
mouth
75.0% 99.0% 66.7% 99.3% 98.3%
13. Burning pain in the limbs 65.5% 92.7% 66.7% 92.3% 87.7%
14. Shooting pain/pins & 
needles
92.8% 93.7% 91.3% 94.8% 93.3%
Domains
Sensitivity Specificity
Positive 
Predictive Value
Negative 
Predictive Value
Accuracy
1. Musculoskeletal pain 95.1% 92.9% 98.3% 81.3% 94.7%
2. Chronic pain 80.0% 86.7% 80.0% 86.7% 84.0%
3. Fluctuation-related pain 92.4% 72.0% 72.2% 92.4% 81.0%
4. Nocturnal pain 94.0% 89.4% 91.9% 92.2% 92.0%
5. Oro-facial pain 85.0% 98.1% 87.2% 97.7% 96.3%
6. Discoloration, 
oedema/swelling
79.1% 89.0% 75.8% 90.7% 86.0%
7. Shooting pain/pins & needles 92.8% 93.7% 91.3% 94.8% 93.3%
	
	
  
  

 

	
	


	


				
				
						
		

			
	

	

	

• 	 !"
# 	
		$	
		
• 	 			
				!%# 
• 	


	&
	
	

				
&
		
		 	
	'(

!"	#	$			#!	%%&'!	%
!(
#) 
) 	*	
+$				
,--------------  
. 		
	$
+ 	
	
,--------------  
' /
0

	----------------  
1 %0
		$

		$-  
2 				
+
	,------  
3 


$$!#

+	
	$,-------------------------  
4 /
$!#

+	
				

,  
5 		*$$	
$	$	
	$


		$

		+
	

$

,---  
6 			
	$	$	---------  
)($-------------------------------  
))		$$		$	$	---------------------  
).7$

		---------------------------  
)'7$	
+	

		
$	, 
)1	$8

	
--------------------  
21 
 
Supplementary material
Assesments
For both patients and controls, information regarding age, sex, and ethnicity was collected. For 
patients, information regarding the duration of PD (in years), years of treatment for PD, current 
treatment, and surgery was also addressed.
In addition to the KPPQ, information for each patient was collected using the following validated 
instruments for PD: 
1. The KPPS [13], a specific measure of different pain modalities for PD patients. It includes 14 
items grouped in seven domains (musculoskeletal, chronic, fluctuation-related, nocturnal, oro-
facial, discolouration and oedema/swelling, and radicular pain). The score for each item is the 
product of severity (0 to 3) and frequency (0 to 4). Total scores for each domain are obtained by 
summing the corresponding items and for the overall scale by summing the domain scores.
2. The original Hoehn and Yahr classification (HY), which measures the staging of PD on a 
scale from one to five with one being unilateral expression of disease and five being the most
severe stage [16].
3. The Scales for Outcomes in Parkinson’s Disease-Motor (SCOPA-Motor), which measures 
motor impairment (10 items), activities of daily living (7 items), and motor complications (4 
items) [17].
4. The Non-Motor Symptoms Scale for PD (NMSS) [18], a 30-item questionnaire grouped in 9 
domains: cardiovascular (2 items), sleep/fatigue (4 items), mood/cognition (6 items), perceptual 
problems/hallucinations (3 items), attention/memory (3 items), gastrointestinal tract (3 items), 
urinary function (3 items), sexual function (2 items), and miscellaneous (4 items).
5. The Clinical Impression of Severity Index for PD (CISI-PD) [19], a clinical estimate of the PD 
global severity in four areas: motor signs, disability, motor complications, and cognitive status.
6. Visual Analog Scales (VAS) for pain severity and frequency [20]. A total score (VAS-TS) was 
obtained by multiplying the two individual scores.
7. Hospital Anxiety and Depression Scale (HADS) [21], a self-administered, 14-item instrument 
to measure depression and anxiety disorders in non-psychiatric outpatients.
8. European Quality of Life – 5 Dimensions Scale (EQ-5D) [22], a generic, preference-based 
health-related quality of life (HRQoL) measure. It includes three components: (1) a descriptive
part, consisting of 5 items, that can then be converted into a value (EQ-Index) representing the 
overall HRQoL; (2) a question about change in health status in the preceding 12 months; and 
(3) a visual analogue scale (EQ-VAS) for assessment of current health state.
9. PD Quality of Life Questionnaire (PDQ-8) [23], an 8-item instrument that specifically 
measures HRQoL in PD;
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10. Parkinson’s Disease Sleep Scale-Version 2 (PDSS-2) [24], an updated version of the 15-
item PDSS.
Data Analysis
Data from each center were anonymized and sent to the National Center of Epidemiology, 
Carlos III Institute of Health, Madrid (Spain) for analysis under the supervision of PMM.
Distribution of data was not normal (Shapiro-Francia test); therefore, non-parametric statistics
were used. For each participant, a KPPQ “total score” (KPPQ-TS) was calculated by summing 
the number of “Yes” responses. Also, to compare the performance of the KPPQ with the KPPS 
that was taken as “gold standard,” the KPPQ items were grouped in domains according to those 
of the scale.   
Differences between patients and controls with respect to demographic data were analyzed 
using the chi-square and Mann-Whitney U tests. The prevalence of the diverse types of pain 
assessed in the questionnaire was determined for each item by the proportion of individuals 
responding positively. In patients, a comparison of the prevalence for each item obtained from 
the KPPS application was carried out considering a score of 0 as the absence of the symptom 
“positive response”) as indicative of the presence of the symptom. The 
McNemar chi-square test was used to determine the statistical significance of the differences. 
Furthermore, Spearman rank correlation coefficients between the KPPQ-TS and scores of the 
other aforementioned pain measures were assessed to determine convergent validity. In 
addition, the correlation between the KPPQ-TS and other variables in the study was calculated. 
A high correlation (rS >0.70) was hypothesized with the KPPS total score (sum of the 14 items´ 
and generic measures.
For test-retest reliability, the percentage of agreement, Cohen’s kappa index for items, and ICC 
(1-way, random effect) for the KPPQ-TS were determined.
Cohen’s kappa was used to determine the concordance between the prevalence detected by 
corresponding items of KPPQ and KPPS. In addition, a KPPS “total score of prevalence” was 
calculated as with the KPPQ-TS, and intraclass correlation coefficient (ICC, 2-way, random 
effect) was used to further analyze the concordance between both “total scores.”
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Finally, sensitivity, specificity, positive and negative predictive values, and accuracy of the 
KPPQ items and domains were calculated against the corresponding components of the KPPS, 
which were considered the gold standard. 
